查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1963988

乙型肝炎治療市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、治療方法、分銷管道、地區和競爭格局分類，2021-2031年

Hepatitis B Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Treatment, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球乙肝治療市場預計將從 2025 年的 51.1 億美元成長到 2031 年的 65.2 億美元，複合年成長率為 4.14%。

該市場涵蓋免疫調節劑和抗病毒藥物的分銷，這些藥物旨在抑制病毒複製並減輕肝損傷。推動該產業發展的關鍵因素包括全球慢性感染疾病的不斷增加，以及各國政府加強篩檢和疫苗接種力度，凸顯了開發有效治療方案的迫切性。根據世界衛生組織（世衛組織）估計，到2024年，全球將有約2.54億人感染慢性B型肝炎。

市場概覽
預測期 2027-2031
市場規模：2025年 51.1億美元
市場規模：2031年 65.2億美元
複合年成長率：2026-2031年 4.14%
成長最快的細分市場 外科手術
最大的市場 北美洲

另一方面，市場擴張的一大障礙是漏診率居高不下，尤其是在開發中國家。終身治療費用高昂，加上醫療基礎設施不足，導致許多感染者無法獲得必要的治療。該疾病的高發病率與低確診病例數之間的巨大差距限制了具有商業性可行性的市場規模，並對旨在進行全球擴張的製藥公司構成了重大挑戰。

市場促進因素

對功能性治癒療法的研發投入不斷增加，正從根本上改變全球B型肝炎治療市場。研究重點正從終身抑制病毒毒力模式轉向恢復免疫調節功能的有限療程治療。製藥創新者正積極探索新的治療方法，例如小干擾RNA和衣殼組裝調節劑，這些療法會攻擊病毒生命週期的不同階段，以實現持續的血清學清除。這些努力已取得令人鼓舞的臨床成果。例如，2025年5月，Vir Biotechnology公司公佈了初步的II期臨床試驗數據，顯示其在研聯合治療在特定患者亞群中實現了15%的功能性治癒率。這表明，治療策略正朝著克服現有核苷類似物局限性的根治性治療方法轉變。

同時，政府主導的篩檢和免疫接種舉措的擴大正在改善患者的檢出率和治療可及性，尤其是在感染率高的地區。在加強預防資源取得的國際夥伴關係的支持下，各國衛生策略正日益採納消除病毒的目標。根據乙肝基金會2024年度報告，全球疫苗免疫聯盟（Gavi Alliance）於2024年6月在32個非洲國家啟動了B肝新生兒疫苗接種宣傳活動。這些公共衛生措施正在增加確診患者的數量，並增強抗病毒藥物生產商的商業性前景。吉利德科學公司在2025年2月宣布，其2024年全年產品銷售額（不包括Veklur）成長了8%，主要得益於其肝病治療產品組合的成長，這一趨勢也印證了上述趨勢。

市場挑戰

限制B型肝炎治療市場經濟發展的主要因素是嚴重的漏診率。儘管全球盛行率顯示抗病毒藥物的潛在使用者群體龐大，但由於絕大多數人並不了解自身感染狀況，商業性可獲得的市場規模要小規模。這種普遍存在的認知不足導致現有病例數與積極尋求醫療服務的患者人數之間存在巨大差距，從而有效地限制了藥品生產商的商機。

診斷缺口直接限制了處方量，阻礙了現有藥物的廣泛應用。儘管庫存充足，但只要大多數感染者仍未納入醫療體系，製藥公司的成長就面臨瓶頸。世界衛生組織（世衛組織）預測，到2024年，只有13%的慢性B型肝炎患者能夠得到診斷。這一數字凸顯出，目前製藥動態僅服務部分患者群體，導致市場潛在需求遠超實際銷售。

市場趨勢

透過活化宿主減弱的T細胞反應，治療性疫苗的臨床試驗正成為實現持續病毒控制的關鍵策略重點。與主要抑制病毒複製的標準抗病毒藥物不同，這些實驗性疫苗旨在刺激特異性免疫，從而使患者能夠完成終身治療。這一策略正在穩步推進。在2024年11月發布的關於2b期臨床試驗結果的新聞稿中，Valinsus Biotherapeutics公司報告稱，接受候選疫苗VTP-300治療的8名受試者實現了乙肝表面抗原清除，其中2名受試者達到了功能性治癒的標準，這凸顯了疫苗克服免疫耐受的潛力。

同時，市場對具有免疫調節作用的候選藥物，特別是旨在快速降低病毒抗原量的單株抗體，越來越感興趣。研發人員正致力於開發能夠清除循環乙型肝炎表面抗原（HBsAg）並消除關鍵免疫抑制機制以促進康復的藥物。這一趨勢在近期的臨床結果中得到了印證。 2024年11月，Blue Jay Therapeutics公司宣布，所有每週接受300毫克單株抗體BJT-778治療的受試者，均在第44週達到病毒學反應。這項進展表明，整個產業正朝著免疫療法的方向發展，免疫療法與直接抗病毒藥物聯合使用，可提高功能性治癒率。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球B型肝炎治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（急性、慢性）
    • 治療方法（免疫調節藥物、抗病毒藥物、疫苗、手術）
    • 通路（醫院藥局、零售藥局、網路藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美B型肝炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲乙型肝炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區乙型肝炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲B型肝炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲B型肝炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球B型肝炎治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Bristol-Myers Squibb
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Accord Healthcare Inc.
  • Apotex Corp.
  • Arbutus Biopharma Corp
  • Arrowhead Pharma Inc
  • Aurobindo Pharma Limited
  • Lupin Pharmaceuticals Inc.
  • Merck & Co. Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17499

The Global Hepatitis B Treatment Market is projected to expand from USD 5.11 Billion in 2025 to USD 6.52 Billion by 2031, registering a CAGR of 4.14%. This market encompasses the distribution of immune modulators and antiviral medications designed to suppress viral replication and mitigate liver injury. Key factors driving this industry include the growing worldwide incidence of chronic infections alongside enhanced governmental efforts regarding screening and vaccination, highlighting the urgent requirement for potent therapeutic solutions. As reported by the World Health Organization, an estimated 254 million individuals globally were living with chronic hepatitis B infection in 2024.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 5.11 Billion
Market Size 2031USD 6.52 Billion
CAGR 2026-20314.14%
Fastest Growing SegmentSurgery
Largest MarketNorth America

Conversely, a significant obstacle retarding market expansion is the high frequency of underdiagnosis, especially within developing nations. The expensive nature of lifelong therapy combined with insufficient healthcare infrastructure prevents a large segment of the infected population from receiving essential care. This gap between the high prevalence of the disease and the low volume of diagnosed patients constrains the commercially viable market, establishing a substantial hurdle for pharmaceutical firms seeking to broaden their global presence.

Market Driver

Increased research and development funding for functional cure therapies is fundamentally transforming the Global Hepatitis B Treatment Market, moving from lifelong viral suppression models to finite treatment courses that reinstate immune regulation. Pharmaceutical innovators are actively exploring new modalities, such as small interfering RNAs and capsid assembly modulators, which attack distinct phases of the viral lifecycle to realize sustained seroclearance. These efforts are producing encouraging clinical results; for instance, Vir Biotechnology reported in May 2025 that preliminary phase 2 study data showed its investigational combination therapy attained a 15% functional cure rate in a specific patient subgroup, signaling a strategic shift toward curative treatments that overcome the limitations of existing nucleoside analogues.

At the same time, the broadening of government-led screening and immunization initiatives is improving patient detection and access to care, especially in areas with high infection rates. National health strategies are increasingly adopting viral elimination targets, backed by international partnerships that enhance access to preventative resources. According to the Hepatitis B Foundation's 2024 Annual Report, the Gavi alliance initiated a campaign in June 2024 to roll out the hepatitis B birth dose vaccine in 32 African nations. These public health efforts are enlarging the diagnosed patient base, thereby bolstering the commercial prospects for antiviral producers, a trend reflected by Gilead Sciences in February 2025, when the company announced an 8% rise in full-year 2024 product sales (excluding Veklury) driven largely by its liver disease portfolio.

Market Challenge

The major limitation hindering the full economic development of the hepatitis B treatment market is the substantial rate of underdiagnosis. While the global prevalence indicates a vast pool of potential antiviral users, the commercially accessible market is much smaller because the majority of individuals are unaware of their infection status. This widespread lack of awareness causes a significant disconnect between the number of existing cases and those actively seeking medical treatment, effectively curtailing revenue opportunities for manufacturers of therapeutic agents.

This gap in diagnosis directly limits prescription volumes and hampers the adoption of existing medications. Despite having sufficient inventory, pharmaceutical companies encounter a growth ceiling as long as most infected individuals remain outside the healthcare network. According to the World Health Organization, only 13 percent of people living with chronic hepatitis B had been diagnosed by 2024. This figure underscores that the industry currently serves only a fraction of the total patient population, creating a market dynamic where potential demand significantly outstrips actual sales.

Market Trends

The clinical testing of therapeutic vaccines is becoming a key strategic priority aimed at achieving sustained viral control by revitalizing the host's depleted T-cell response. In contrast to standard antivirals that mainly suppress replication, these experimental vaccines seek to stimulate specific immunity, potentially allowing patients to end lifelong treatment. This strategy is demonstrating real progress; according to a November 2024 press release regarding ongoing Phase 2b trial results, Barinthus Biotherapeutics reported that eight subjects treated with candidate VTP-300 achieved HBsAg loss at some point, with two qualifying as functional cures, highlighting the promise of vaccination in overcoming immune tolerance.

Concurrently, there is a notable market emphasis on immunomodulatory candidates, specifically monoclonal antibodies engineered to swiftly lower viral antigen loads. Developers are focusing on agents capable of depleting circulating hepatitis B surface antigen (HBsAg), thereby eliminating a key immune suppression mechanism to aid recovery. This trend is illustrated by recent clinical achievements; Bluejay Therapeutics announced in November 2024 that 100% of participants receiving a 300 mg weekly dose of their monoclonal antibody BJT-778 achieved a virologic response by Week 44. Such progress signifies a wider industry movement toward immunotherapies that work alongside direct-acting antivirals to improve functional cure rates.

Key Market Players

  • Bristol-Myers Squibb
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Accord Healthcare Inc.
  • Apotex Corp.
  • Arbutus Biopharma Corp
  • Arrowhead Pharma Inc
  • Aurobindo Pharma Limited
  • Lupin Pharmaceuticals Inc.
  • Merck & Co. Inc.

Report Scope

In this report, the Global Hepatitis B Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hepatitis B Treatment Market, By Type

  • Acute
  • Chronic

Hepatitis B Treatment Market, By Treatment

  • Immune Modulator Drugs
  • Antiviral Drugs
  • Vaccines
  • Surgery

Hepatitis B Treatment Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Hepatitis B Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hepatitis B Treatment Market.

Available Customizations:

Global Hepatitis B Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Hepatitis B Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Acute, Chronic)
    • 5.2.2. By Treatment (Immune Modulator Drugs, Antiviral Drugs, Vaccines, Surgery)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Hepatitis B Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Treatment
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Hepatitis B Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Treatment
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Hepatitis B Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Treatment
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Hepatitis B Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Treatment
        • 6.3.3.2.3. By Distribution Channel

7. Europe Hepatitis B Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Treatment
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Hepatitis B Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Treatment
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Hepatitis B Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Treatment
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Hepatitis B Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Treatment
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Hepatitis B Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Treatment
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Hepatitis B Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Treatment
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Hepatitis B Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Treatment
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Hepatitis B Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Treatment
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Hepatitis B Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Treatment
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Hepatitis B Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Treatment
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Hepatitis B Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Treatment
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Hepatitis B Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Treatment
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Hepatitis B Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Treatment
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Hepatitis B Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Treatment
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Hepatitis B Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Treatment
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Hepatitis B Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Treatment
        • 9.3.3.2.3. By Distribution Channel

10. South America Hepatitis B Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Treatment
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Hepatitis B Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Treatment
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Hepatitis B Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Treatment
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Hepatitis B Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Treatment
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Hepatitis B Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Bristol-Myers Squibb
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Gilead Sciences, Inc.
  • 15.3. GlaxoSmithKline PLC
  • 15.4. Accord Healthcare Inc.
  • 15.5. Apotex Corp.
  • 15.6. Arbutus Biopharma Corp
  • 15.7. Arrowhead Pharma Inc
  • 15.8. Aurobindo Pharma Limited
  • 15.9. Lupin Pharmaceuticals Inc.
  • 15.10. Merck & Co. Inc.

16. Strategic Recommendations

17. About Us & Disclaimer